Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Castle Biosciences, Inc.
CSTL
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $749.5M
$24.11
▼ -2.43%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.59 - $44.28
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 23.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary multi-gene expression profiling technology with clinical validation
- Comprehensive test portfolio covering multiple dermatological cancers
- Strong physician relationships and integrated diagnostic workflow
- Established reimbursement pathways and payer coverage
- First-mover advantage in precision diagnostics for skin cancer
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Rising incidence of melanoma and non-melanoma skin cancers globally
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Stable
-0.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CSTL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 6, 2026
Reported EPS of -$0.49 vs -$0.49 consensus (0.0% surprise). Revenue of $84.2M vs $79.2M expected (+6.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+31%
+21%
-1%
-3%
+1%
-5%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$87.0M
$85.8M
$86.3M
$88.0M
$86.2M
$83.0M
$87.0M
$83.7M
Margins · last 8Q
Gross
—
Operating
—
Profit
-17.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$37.50
▲ +55.5% vs $24.11
Latest: Roth Capital · Jun 24, 2026
2 analysts covering